Nj State Employees Deferred Compensation Plan Halozyme Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $877 Million
- Q3 2025
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 27,800 shares of HALO stock, worth $1.9 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
27,800
Previous 27,800
-0.0%
Holding current value
$1.9 Million
Previous $1.45 Million
40.94%
% of portfolio
0.23%
Previous 0.18%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
641Shares Held
126MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$794 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$405 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$237 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$232 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.51B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...